Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen

By Scarpi E.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 2, 2001-07 ,pp. : 101-110

Springer Publishing Company

Access to resources Recommend Favorite

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

By Nielsen Kirsten  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 345-355

Springer Publishing Company

Access to resources Recommend Favorite

Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen

By Biron-Shental T.   Tepper R.   Fishman A.   Shapira J.   Cohen I.  

Gynecologic Oncology, Vol. 90, Iss. 2, 2003-08 ,pp. : 382-386

Elsevier

Access to resources Recommend Favorite

The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen

By Billgren A.-M.   Rutqvist L.E.   Johansson H.   Hagerstrom T.   Skoog L.  

European Journal of Cancer, Vol. 36, Iss. 11, 2000-07 ,pp. : 1374-1380

Elsevier

Access to resources Recommend Favorite

Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes

By Mehta Madhura  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 861-868

Springer Publishing Company

Access to resources Recommend Favorite